GE HealthCare (GEHC) insider trading
Insider activity, historical context and SEC filings · data through Nov 20, 2026
Insiders put their own money in: $6.4M of open-market buys. See how similar setups did below.
Past insider buys here: 8 of 8 beat the S&P 500 over the next 90 days. See each one ↓
Label: Strong buying · based on open-market trades (codes P and S), last 12 months. Not a rating or advice.- Next earnings expected around Jan 21, 2027 (estimate from past release dates). Insiders usually trade in the weeks after results; past reactions ↓
Purchase Kevin Lobo, Director bought 10,000 shares at $64.18 ($642K).
- Trade date
- May 22, 2026
- Disclosed to the SEC
- May 26, 2026
- Type
- Open-market purchase (code P)
Read the original SEC filing ↗All GEHC insider trades ↓
Insiders have two business days to report a trade to the SEC, so filings (and our alerts) always come after the trade, never in real time.
GEHC insider transactions (Form 4)
Open-market purchases and sales. 70 grants, option exercises and tax withholdings are not shown.
| Filed | Insider | Type | Shares | Price | Value | Since | Score |
|---|---|---|---|---|---|---|---|
| May 26SEC | Kevin LoboDirectorFirst buyStake +229% | Buy | 10,00014,363 held (+229%) | $64.18 | $642K | +27.4% | — |
| May 13SEC | Rodney F. HochmanDirectorFirst buyNew position | Buy | 1,618new position | $62.03 | $100K | +31.8% | — |
| May 11SEC | Watkin Phoebe L. YangDirectorFirst buy | Buy | 1,00013,702 held (+8%) | $63.01 | $63K | +29.8% | — |
| May 7SEC | H. Lawrence Culp Jr.DirectorFirst buy in 3 yrsStake +115% | Buy | 80,805151,207 held (+115%) | $61.88 | $5.0M | +32.1% | — |
| May 7SEC | William J. StrombergDirectorFirst buy | Buy | 1,00015,330 held (+7%) | $61.69 | $62K | +32.6% | — |
| May 1SEC | James SaccaroCFOFirst buy | Buy | 3,31087,471 held (+4%) | $60.60 | $201K | +34.9% | — |
| Apr 30SEC | Peter J. ArduiniCEO, PresidentFirst buy | Buy | 4,169259,424 held (+2%) | $59.92 | $250K | +36.5% | — |
| Apr 30SEC | Frank R. JimenezGc & Corporate Secretary | Buy | 1,75093,932 held (+2%) | $60.45 | $106K | +35.3% | — |
Similar past setups: not applicable. There aren't enough comparable past cases for GEHC's latest buying to report odds. When insiders buy, this section shows how 6,290 similar past buys did over 90 days. How we calculate this →
Play with GEHC in the Research Lab
Pre-set to GEHC's latest insider buy of $10K or more (May 26, 2026: Kevin Lobo, Rodney F. Hochman, $742K). Tap to change anything.
Quick backtest: did buys like this beat the market?
Tap a setting to see how 6,290 past insider buys did.
- After GEHC's buys7, 30 and 90 days later, losses included
- Find buys like this"insiders bought over $250K after a 20% drop in the last 12 months"
- Compare GEHC vs KODInsider buying and selling side by side
- GEHC's board links6 companies share insiders with GEHC
- Play Insider Call5 real buys a day: guess which beat the market
Share price and insider trades
GE HealthCare insider trading at a glance (Nov 20, 2026): in the past 12 months, 8 insiders bought $6.4M and 0 sold $0 of GEHC stock on the open market, including a cluster buy that began Apr 30, 2026; P/E 16.6 vs. a sector median of 25.0.
By InsiderPrint Research Desk · Updated · Sources: SEC EDGAR Form 4 filings, FINRA short-sale volume · How we calculate this
GEHC insider buying and selling by quarter
Open-market purchases (green, above the line) and sales (red, below), by trade date.
| Quarter | Bought | Purchases | Sold | Sales |
|---|---|---|---|---|
| Q4 2026 | — | 0 | — | 0 |
| Q3 2026 | — | 0 | — | 0 |
| Q2 2026 | $6.4M | 8 | — | 0 |
Valuation, profit and volume
Source: SEC filings, as of Nov 16, 2026. Volume and paper profit use daily closing prices.
Summary
Over the past 12 months, 8 GE HealthCare insiders reported open-market purchases totaling $6.4M, while 0 insiders reported sales totaling $0. The most recent cluster buy began on Apr 30, 2026, when 7 insiders bought a combined $5.8M.
GEHC earnings: how the stock reacted
Each quarterly results release (SEC 8-K Item 2.02), the trend before it, insider trades in the 30 days before, and the 2-day market reaction. “E” marks releases on the chart above.
| Release | 15 days before | Insiders, 30 days before | Reaction (2 days) | Next 30 days |
|---|---|---|---|---|
| Oct 28, 2026 | +5.0% | None | +7.5%S&P -0.0% | pending |
| Jul 29, 2026 | -1.8% | None | +9.1%S&P +0.1% | +2.6% |
| Jul 23, 2026 | -5.4% | None | -1.3%S&P -1.1% | +23.5% |
| Apr 29, 2026 | -7.2% | None | -11.2%S&P +1.0% | +2.5% |
| Feb 4, 2026 | -3.6% | None | +4.5%S&P -1.7% | -9.8% |
| Oct 29, 2025 | +10.6% | None | -5.5%S&P -1.1% | +6.7% |
| Jul 30, 2025 | +4.4% | None | -8.2%S&P -0.5% | +3.4% |
| Apr 30, 2025 | +5.8% | None | -0.6%S&P +0.7% | +4.2% |
Most companies bar insiders from trading in the weeks before results, so pre-earnings purchases are rare and often made by directors or under pre-set plans. Past reactions don't predict future ones.
GEHC short selling
Daily short-sale volume as a share of trading volume (FINRA), with the 20-day average.
This is short volume from off-exchange trades, not short interest. It includes market makers' routine hedging, so 40–50% is normal; what stands out is a ratio well above the stock's own average. Insiders buying while shorts pile in →
Members of Congress who traded GEHC
From STOCK Act disclosures. Reported up to 45 days after the trade, in dollar ranges.
| Member | Trade | Traded | Reported | Since trade |
|---|---|---|---|---|
| Alan ArmstrongSenate | Bought $1,001 - $15,000 | Mar 27, 2026 | Jul 21, 2026 | +18.2% |
What happened after GEHC insiders bought
Each open-market purchase, measured from the day the filing became public, next to the S&P 500 over the same days. Losses included; "pending" means the days haven't passed yet.
| Filed | Insider | Bought | 7 days | 30 days | 90 days |
|---|---|---|---|---|---|
| May 26, 2026 | Kevin LoboDirector | $642K | -3.4%-4.6% vs S&P | +1.2%+3.1% vs S&P | +15.7%+13.7% vs S&P |
| May 13, 2026 | Rodney F. HochmanDirector | $100K | +3.8%+4.0% vs S&P | +5.3%+5.4% vs S&P | +17.6%+13.5% vs S&P |
| May 11, 2026 | Watkin Phoebe L. YangDirector | $63K | -0.3%-0.2% vs S&P | +3.3%+5.2% vs S&P | +18.3%+13.5% vs S&P |
| May 7, 2026 | H. Lawrence Culp Jr.Director | $5.0M | +2.2%-0.1% vs S&P | +5.4%+4.4% vs S&P | +14.6%+9.1% vs S&P |
| May 7, 2026 | William J. StrombergDirector | $62K | +2.2%-0.1% vs S&P | +5.4%+4.4% vs S&P | +14.6%+9.1% vs S&P |
| May 1, 2026 | James SaccaroCFO | $201K | +4.0%+1.6% vs S&P | +2.7%-2.5% vs S&P | +14.7%+11.5% vs S&P |
| Apr 30, 2026 | Peter J. ArduiniCEO, President | $250K | +0.8%-1.0% vs S&P | +3.0%-2.5% vs S&P | +18.2%+16.5% vs S&P |
| Apr 30, 2026 | Frank R. JimenezGc & Corporate Secretary | $106K | +0.8%-1.0% vs S&P | +3.0%-2.5% vs S&P | +18.2%+16.5% vs S&P |
Insiders at GE HealthCare
| Insider | Bought | Sold | Last filing | Past buys beat S&P | Score |
|---|---|---|---|---|---|
| H. Lawrence Culp Jr.Director | $5.0M | — | May 11, 2026 | — | — |
| Kevin LoboDirector | $642K | — | May 26, 2026 | — | — |
| Peter J. ArduiniCEO, President | $250K | — | Sep 4, 2026 | — | — |
| James SaccaroCFO | $201K | — | May 1, 2026 | — | — |
| Frank R. JimenezGc & Corporate Secretary | $106K | — | Sep 4, 2026 | — | — |
| Rodney F. HochmanDirector | $100K | — | May 13, 2026 | — | — |
| Watkin Phoebe L. YangDirector | $63K | — | May 11, 2026 | — | — |
| William J. StrombergDirector | $62K | — | May 11, 2026 | — | — |
| Neal Joseph SandyCEO | — | — | Nov 18, 2026 | — | — |
| William K. GroganCFO | — | — | Sep 16, 2026 | — | — |
| Taha Kass-HoutCTO | — | — | Sep 4, 2026 | — | — |
| Philip RackliffeCEO | — | — | Sep 4, 2026 | — | — |
| Kevin Michael O'NeillCEO | — | — | Sep 4, 2026 | — | — |
| Adam Y. HoltonChief People Officer | — | — | Sep 4, 2026 | — | — |
| Catherine EstrampesChief Commer. & Growth Officer | — | — | Sep 4, 2026 | — | — |
| George A. NewcombChief Accounting Officer | — | — | Sep 4, 2026 | — | — |
| Jeannette BankesCEO | — | — | Sep 3, 2026 | — | — |
| Catherine A. LesjakDirector | — | — | May 11, 2026 | — | — |
| Anne T. MaddenDirector | — | — | May 11, 2026 | — | — |
| Roland RottCEO | — | — | Mar 4, 2026 | — | — |
Board links: companies that share insiders with GEHC
Directors and executives who filed Form 4s for GEHC and another company in the last 12 months.
- GEGE Aerospace H. Lawrence Culp Jr. Director here · CEO, Chair at GE · latest filing Nov 12, 2026Catherine A. Lesjak Director here · Director at GE · latest filing May 11, 2026
- DOCSDoximity Watkin Phoebe L. Yang Director here · Director at DOCS · latest filing Oct 2, 2026
- HIIHuntington Ingalls Industries Frank R. Jimenez Gc & Corporate Secretary here · Director at HII · latest filing Oct 2, 2026
- PHParker Hannifin Kevin Lobo Director here · Director at PH · latest filing May 26, 2026
- SYKStryker Kevin Lobo Director here · CEO, Chair at SYK · latest filing May 26, 2026
- XYLXylem William K. Grogan CFO here · CFO at XYL · latest filing Sep 16, 2026
Insider activity at other Health Care companies
Same sector, ranked by insider buying in the last 90 days.
GEHC stock: common questions
Are GE HealthCare insiders buying GEHC stock?
In the past 12 months, 8 insiders reported open-market purchases of GEHC worth $6.4M. The latest was Director Kevin Lobo bought $642K of GEHC at $64.18 — first open-market purchase in our records; raises the stake by 229%.
Are GE HealthCare insiders selling GEHC stock?
No. No GE HealthCare insider reported an open-market sale of GEHC in the past 12 months.
Where does this data come from?
Every transaction comes from Form 4 filings that insiders must submit to the SEC within two business days of a trade. We pull them from SEC EDGAR every night.
What is GEHC's P/E ratio?
GEHC trades at about 16.6 times trailing earnings, compared with a median of 25.0 for the Health Care sector.
What is GEHC's 52-week range?
Over the past year GEHC has traded between $59.45 and $88.03. It last closed at $81.77 on Nov 19, 2026.